A systematic review published this week has reignited one of the most contentious debates in neurology: whether the new generation of Alzheimer's drugs actually helps patients in ways that matter.

The analysis, which examined clinical trials of anti-amyloid monoclonal antibodies, concluded that this drug class delivers minimal clinical benefit to patients despite successfully reducing amyloid plaques in the brain. But the findings have drawn immediate and sharp criticism from Alzheimer's researchers, who argue the review fatally conflates experimental failures with recently approved treatments that have shown genuine, if modest, efficacy.

The Core Disagreement

Anti-amyloid drugs work by targeting beta-amyloid, the protein that forms sticky plaques in the brains of Alzheimer's patients. For decades, clearing these plaques has been the dominant therapeutic strategy, based on the amyloid hypothesis—the theory that amyloid accumulation drives the disease's progression.

The meta-analysis in question pooled data from multiple clinical trials of drugs in this class. Its authors concluded that even when these medications successfully reduced amyloid burden, the corresponding improvements in cognitive function and daily living activities were too small to be clinically meaningful for patients.

Many Alzheimer's specialists immediately challenged this methodology. Their central objection: the analysis treated all anti-amyloid drugs as equivalent, combining data from experimental compounds that failed in trials with lecanemab (Leqembi) and donanemab (Kisunla)—two drugs that received FDA approval in 2023 and 2024 respectively after demonstrating statistically significant benefits in large trials.

What the Approved Drugs Actually Showed

According to the original trial data reported by the pharmaceutical companies and published in peer-reviewed journals, both lecanemab and donanemab slowed cognitive decline by approximately 25-35% compared to placebo over 18 months in patients with early-stage Alzheimer's disease.

In practical terms, this translated to a difference of roughly 0.5 points on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), an 18-point scale measuring cognitive and functional abilities. Critics of these drugs argue this difference is too subtle for patients or caregivers to notice. Supporters counter that any slowing of decline matters enormously to families facing a progressive, fatal disease with no other disease-modifying options.

The drugs also carry significant risks. Both can cause brain swelling and microbleeds visible on MRI scans, a side effect known as ARIA (amyloid-related imaging abnormalities). Several trial participants experienced serious complications, and at least three deaths have been potentially linked to treatment, according to FDA safety reports.

The Broader Context

This debate reflects deeper tensions in how we evaluate treatments for neurodegenerative diseases. Traditional drug approval has focused on statistical significance—whether a treatment performs better than placebo in controlled trials. But for chronic, progressive conditions like Alzheimer's, statistical significance doesn't always translate to effects patients can feel.

The controversy also highlights the astronomical stakes involved. An estimated 6.7 million Americans currently live with Alzheimer's disease, and the approved anti-amyloid drugs cost approximately $26,500 annually per patient. Medicare's decision to cover these treatments has significant budgetary implications.

Previous attempts to develop anti-amyloid drugs ended in high-profile failures. Solanezumab, bapineuzumab, and gantenerumab all successfully reduced amyloid plaques but showed no cognitive benefit in Phase 3 trials. These failures led some researchers to question whether the amyloid hypothesis itself was flawed—whether targeting plaques addresses a symptom rather than a cause of the disease.

What Researchers Are Saying

Alzheimer's specialists who criticized the new meta-analysis argue that lumping these failed drugs together with lecanemab and donanemab obscures crucial differences. The approved drugs target different forms of amyloid, are administered at different stages of disease, and achieved far more substantial plaque reduction than earlier compounds.

They also point out that the approved drugs were tested in patients with confirmed amyloid pathology and early-stage disease—more precise patient selection than many earlier trials employed. This specificity, they argue, is exactly why these drugs succeeded where others failed.

Defenders of the meta-analysis counter that their statistical approach is standard methodology for systematic reviews, designed to provide an overview of an entire drug class rather than cherry-picking successful examples. They maintain that even the approved drugs show benefits too small to justify their costs and risks for most patients.

The Path Forward

The debate underscores a fundamental question facing Alzheimer's research: Is modest slowing of decline sufficient, or should the field pursue more transformative approaches?

Several alternative strategies are now in clinical trials, including drugs targeting tau protein (another Alzheimer's hallmark), anti-inflammatory approaches, and treatments aimed at supporting brain metabolism. Some researchers advocate for combination therapies that address multiple aspects of the disease simultaneously.

Meanwhile, the infrastructure for early detection continues to develop. Blood tests that can identify amyloid and tau pathology years before symptoms appear are becoming commercially available, raising the possibility of treating patients even earlier in the disease process—when interventions might be more effective.

For now, the approved anti-amyloid drugs remain the only treatments that target Alzheimer's underlying biology rather than just managing symptoms. Whether they represent a meaningful breakthrough or an expensive disappointment depends largely on perspective—and on what we demand from treatments for a disease that remains, fundamentally, incurable.